Précédent
Suivant
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
EQUIPREN
|
VBY-01 |
|
|
|
|
|
|
|
Discover the effects of mesenchymal stem cells on inflammatory and immune diseases developed by Vetbiobank
Vetbiobank has developed a bank of cryopreserved equine amniotic membrane grafts; they are qualified in the same way as equine neonatal cells, and are being tested in compassionate situations to assist in the healing of corneal ulcers, lacerationsKor wounds in horses, dogs or cats that do not respond to conventional treatments.
Vetbiobank is developing a placental blood-based serum whose safety and efficacy has been tested by a VetAgro-Sup research team in a pilot clinical trial in horses with refractory corneal ulcers.
Vetbiobank for several years, has been conducting a research program on the secretion of bioactive molecules and particles by stem cells. Given the scope of the program, our R&D teams have set up key partnerships with academic research teams to characterize these capacities and to evaluate the opportunity to develop an acellular drug.
To learn more about the availability of these products
To learn more about the availability of these products
The scientific literature shows that the potential application of mesenchymal stem cells could be extended to other indications than those currently explored by Vetbiobank such as degeneration of the intervertebral disc; Anti-infectious role; IBD; Dry keratoconjunctivitis; Tendinitis; Diabetes.
If you wish to evaluate other research programs concerning this then contact us.
Company
Technologies
Products
Partners
News
© 2021 Vetbiobank All Rights Reserved
Ask your veterinarian for the price of a stem cell injection at his clinic.
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
CANIPREN
|
VBX-01 |
VBX-01 |
VBX-01 |
|
|
|
|
|
|
|
|
CA0102 |
|
|
|
|
|
|
|
|||
|
CA0103 |
|
|
|
|
|
|
|
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
FELIPREN
|
FE0101 |
|
|
|
|
|
|
|
|
FE0102 Chronic kidney failure |
|
|
|
|
|
|
|
|
|
FE0103 |
|
|
|
|
|
|
|
| Range | Product | Development & optimization | Proof of Concept | Pilot study |
Industrialisation / Manufacturing |
Pivotal study | Approval | Marketing Launch |
|---|---|---|---|---|---|---|---|---|
|
EQUIPREN
|
EQ0101 |
|
|
|
|
|
|
|
